Shanghai, China - VitaFlow^® Transcatheter Aortic Valve and Delivery System ("VitaFlow^®"), in-house developed by MicroPort CardioFlow has been admitted into the "Green Path" by the China Food and Drug Administration ("CFDA"), a special fast-track procedure for innovative medical devices to gain CFDA approval.

Suzhou, China – From March 22 to March 25, MicroPort^® Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort^® CardioFlow"), a wholly owned subsidiary of Shanghai MicroPort^® Medical (Group) Co., Ltd. ("MicroPort^®"), attended CIT 2018 and released the one-year clinical outcome of VitaFlow^® Transcatheter Aortic Valve and Delivery System ("VitaFlow^®").

Shanghai, China – On August 22, MicroPort Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort^®CardioFlow"), a wholly owned subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort^®"), entered into financing agreements at a consideration of RMB430million and achieved a valuation of RMB2.1 billion after this round of financing.